Galapagos receives €4 million in milestones from Servier
Galapagos NV announced that it reached milestones in its osteoarthritis alliance with Servier, resulting in payments in 2010 revenues totaling €4 million from Servier.
In July 2010, Servier and Galapagos announced their alliance to develop new medicines for the treatment of osteoarthritis. Galapagos is responsible for the discovery and development of new candidate drugs and Servier has an exclusive option to license these after the completion of Phase I clinical trials by Galapagos. To date, Galapagos has received a total of €11 million in payments from Servier under the alliance.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Depomed initiates phase II clinical trial for Gabapentin ER in pain indication
Diabetes drug found no better than placebo at treating NAFLD
Crucell and NIH extend Ebola Vaccine Agreement
LibraGen signs partnership agreement with Pierre Fabre Medicament R&D - LibraGen will use its industrial biocatalysis know-how to carry out research into optimizing the synthesis of a pharmaceutical molecule
Heptares secures £21 million in Series A fund raising - Funds to accelerate development of pipeline of small molecules against high-value GPCR drug targets
Auspherix Raises £6Million to Progress its Novel Antibiotics and Establishes UK Operations
CEO of LTS Lohmann Therapie-Systeme AG retires
Ablynx's anti-vWF Nanobody achieves clinical proof-of-concept in Phase II TITAN study - First-in-class potential with orphan drug status for the treatment of acquired thrombotic thrombocytopenic purpura
Sanofi-aventis, Innogenetics, and Inserm to collaborate on Alzheimer's disease
From bacteria to electricity: The future of green energy

Cube Biotech acquires IBA Lifesciences - Two leading innovators of biotech join forces
